Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors

被引:38
作者
Bertotti, Andrea
Bracco, Cecilia
Girolami, Flavia
Torti, Davide
Gastaldi, Stefania
Galimi, Francesco
Medico, Enzo [2 ]
Elvin, Paul [3 ]
Comoglio, Paolo M.
Trusolino, Livio [1 ]
机构
[1] Univ Turin, Sch Med, Inst Canc Res & Treatment, Div Mol Oncol,IRCC,Oncogenom Ctr, I-10060 Turin, Italy
[2] Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC,Lab Funct Gen, I-10060 Turin, Italy
[3] AstraZeneca, Canc & Infect Res Area, Macclesfield, Cheshire, England
关键词
ANCHORAGE-INDEPENDENT GROWTH; CELL LUNG-CANCER; SRC/ABL KINASE INHIBITOR; IN-VIVO; C-SRC; ANTITUMOR-ACTIVITY; TYROSINE KINASES; CARCINOMA CELLS; FACTOR RECEPTOR; FAMILY KINASES;
D O I
10.1158/1078-0432.CCR-10-0106
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We examined whether inhibition of Src tyrosine kinase, a downstream effector of the MET oncogene, can hinder the malignant properties of gastric tumors dependent on Met for growth and survival. Experimental Design: Sensitivity to Src inhibition was determined in vitro by measuring clonogenic survival (anchorage-independent growth) and in vivo by establishing xenograft models. Four "Met-addicted" gastric carcinoma cell lines (GTL16, MKN45, HS746T, and SNU5) and three Met-independent gastric carcinoma cell lines (KATO III, AGS, and NCI-N87) were treated with the Src inhibitor saracatinib (AZD0530). In GTL16 and KATO III, Src neutralization was also achieved by dasatinib and RNA interference. The biochemical and transcriptional consequences of Src inhibition were explored using anti-phosphoprotein antibodies and oligonucleotide microarrays. Results: Inhibition of Src in Met-addicted gastric carcinoma cell lines (a) decreased the phosphorylation/activation levels of signaling intermediates involved in cell proliferation and protection from apoptosis and down-modulated the expression of several cell cycle regulators; (b) reduced anchorage-independent growth; (c) enhanced impairment of cell viability produced by Met inhibition; and (d) delayed tumorigenesis in xenotransplantation models. Immunohistochemical analysis of tumor xenograft tissues following systemic treatment with saracatinib showed a reduction of tumor cell proliferation index, increased apoptosis, and diminished phospho-focal adhesion kinase and phospho-paxillin staining. Tumor stroma parameters such as angiogenesis or inflammatory infiltration were unaffected. In clonogenic survival assays, gastric carcinoma cells without addiction to Met were less sensitive than Met-addicted cells to Src inhibition. Conclusions: Src is as a key downstream transducer of Met-driven tumor growth. Targeting Src might provide therapeutic benefit in Met-addicted tumors. Clin Cancer Res; 16(15); 3933-43. (C) 2010 AACR.
引用
收藏
页码:3933 / 3943
页数:11
相关论文
共 36 条
[1]   MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].
Bean, James ;
Brennan, Cameron ;
Shih, Jin-Yuan ;
Riely, Gregory ;
Viale, Agnes ;
Wang, Lu ;
Chitale, Dhananjay ;
Motoi, Noriko ;
Szoke, Janos ;
Broderick, Stephen ;
Balak, Marissa ;
Chang, Wen-Cheng ;
Yu, Chong-Jen ;
Gazdar, Adi ;
Pass, Harvey ;
Rusch, Valerie ;
Gerald, William ;
Huang, Shiu-Feng ;
Yang, Pan-Chyr ;
Miller, Vincent ;
Ladany, Marc ;
Yang, Chih-Hsin ;
Pao, William .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937
[2]   β4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth [J].
Bertotti, Andrea ;
Comoglio, Paolo M. ;
Trusolino, Livio .
JOURNAL OF CELL BIOLOGY, 2006, 175 (06) :993-1003
[3]   Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction [J].
Bertotti, Andrea ;
Burbridge, Mike F. ;
Gastaldi, Stefania ;
Galimi, Francesco ;
Torti, Davide ;
Medico, Enzo ;
Giordano, Silvia ;
Corso, Simona ;
Rolland-Valognes, Gaelle ;
Lockhart, Brian P. ;
Hickman, John A. ;
Comoglio, Paolo M. ;
Trusolino, Livio .
SCIENCE SIGNALING, 2009, 2 (100) :ra80
[4]   Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling [J].
Cantiani, Lara ;
Manara, Maria Cristina ;
Zucchini, Cinzia ;
De Sanctis, Paola ;
Zuntini, Monia ;
Valvassori, Luisa ;
Serra, Massimo ;
Olivero, Martina ;
Di Renzo, Maria Flavia ;
Colombo, Mario Paolo ;
Picci, Piero ;
Scotlandi, Katia .
CANCER RESEARCH, 2007, 67 (16) :7675-7685
[5]   Combined Src and Aromatase Inhibition Impairs Human Breast Cancer Growth In vivo and Bypass Pathways Are Activated in AZD0530-Resistant Tumors [J].
Chen, Yi ;
Guggisberg, Natalia ;
Jorda, Merce ;
Gonzalez-Angulo, Ana ;
Hennessy, Bryan ;
Mills, Gordon B. ;
Tan, Chen-Keat ;
Slingerland, Joyce M. .
CLINICAL CANCER RESEARCH, 2009, 15 (10) :3396-3405
[6]  
Christensen JG, 2003, CANCER RES, V63, P7345
[7]   Drug development of MET inhibitors: targeting oncogene addiction and expedience [J].
Comoglio, Paolo M. ;
Giordano, Silvia ;
Trusolino, Livio .
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (06) :504-516
[8]   Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability [J].
Eliceiri, BP ;
Paul, R ;
Schwartzberg, PL ;
Hood, JD ;
Leng, J ;
Cheresh, DA .
MOLECULAR CELL, 1999, 4 (06) :915-924
[9]   Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells [J].
Emaduddin, Muhammad ;
Bicknell, David C. ;
Bodmer, Walter F. ;
Feller, Stephan M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (07) :2358-2362
[10]   MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].
Engelman, Jeffrey A. ;
Zejnullahu, Kreshnik ;
Mitsudomi, Tetsuya ;
Song, Youngchul ;
Hyland, Courtney ;
Park, Joon Oh ;
Lindeman, Neal ;
Gale, Christopher-Michael ;
Zhao, Xiaojun ;
Christensen, James ;
Kosaka, Takayuki ;
Holmes, Alison J. ;
Rogers, Andrew M. ;
Cappuzzo, Federico ;
Mok, Tony ;
Lee, Charles ;
Johnson, Bruce E. ;
Cantley, Lewis C. ;
Janne, Pasi A. .
SCIENCE, 2007, 316 (5827) :1039-1043